


Abstract

Substantially pure amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A. In addition, this disclosure is directed to a process for the preparation thereof from crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A via orthorhombic isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, of the general formula I



wherein S represents a water-miscible or water-immiscible organic solvent, characterized by the orthorhombic space group $P2_12_12_1$, with average unit cell parameters $a = 8.2$ to 9.7 \AA , $b = 11.5$ to 13.5 \AA , $c = 44.5$ to 47.0 \AA , $\alpha = \beta = \gamma = 90^\circ$, wherein a , b and c represent the crystal axes lengths and α , β and γ represent the angles between the crystal axes.

In addition, pharmaceutical compositions containing the substantially pure amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A are disclosed, as well as a method for the treatment of bacterial and protozoal infections, and inflammation related diseases in humans and animals by administration of a pharmaceutical composition containing same.